AnaptysBio earnings beat by $0.75, revenue topped estimates

AnaptysBio (ANAB) reported Q3 EPS of $0.11, beating estimates by $0.75, with revenue at $30.27M, exceeding expectations of $18.86M. The stock is down 18.30% in 3 months but up 41.25% in 12 months. InvestingPro rates its financial health as 'great performance'.

Original reporting
Published Nov 13, 2026, 6:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANAB
Bullish
high confidence
Mentioned
$ANAB
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANABBullishHigh
01

Why it matters

Earnings beat could attract short-term buying interest and trigger analyst upgrades.

02

Market read

The earnings surprise provides a fresh catalyst for ANAB, offering a short-term trading opportunity.

03

What to watch

Potential upcoming regulatory or clinical trial risks not covered in the release.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

AnaptysBio is a clinical-stage biotech focused on immunology therapies.

Company-level read

Ticker impact

$ANABBullishHigh confidence
Context

AnaptysBio reported Q3 EPS of $0.11, beating estimates by $0.75 and revenue of $30.27M versus $18.86M consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The surprise EPS and revenue beat provide fresh, material information that can move the stock in the short term.

Market effects

Positive earnings may lift sentiment in the biotech sector.

Limited to US-listed biotech investors.

Minimal global impact beyond niche biotech investors.

Counterpoint

The beat may be priced in quickly, limiting upside.

Key entities

  • AnaptysBio

    NASDAQ-listed biotech reporting Q3 results.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.